Oncolytics Biotech, Inc. engages in the provision of development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. The company is headquartered in Calgary, Alberta. The company went IPO on 2000-06-01. The firm is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2-negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.
Mr. Jared Kelly is the Chief Executive Officer of Oncolytics Biotech Inc., joining the firm since 2025.
What is the price performance of Oncolytics Biotech Inc. stock?
The current price of Oncolytics Biotech Inc. is $0.9666, it has increased 0.65% in the last trading day.
What are the primary business themes or industries for Oncolytics Biotech Inc.?
Oncolytics Biotech Inc. belongs to Biotechnology industry and the sector is Health Care
What is Oncolytics Biotech Inc. market cap?
Oncolytics Biotech Inc.'s current market cap is $104.0M
Is Oncolytics Biotech Inc. a buy, sell, or hold?
According to wall street analysts, 5 analysts have made analyst ratings for Oncolytics Biotech Inc., including 1 strong buy, 5 buy, 2 hold, 0 sell, and 1 strong sell